EndoDNA Launches BIOS to Transform Genetic Data into Clinical Action

The platform, which stands for Biomedical Reasoning and Adaptive Inference Network, replaces the company’s legacy myDNALive engine. Unlike consumer DNA tools that focus on isolated variants, BIOS maps genomic data across 21 biological systems, including hormone metabolism, inflammation, and cognitive function. It monitors approximately 1 million validated variants, curating 214 pathways to support real-time clinical decisions.

Functionality relies on four distinct memory networks: World, which draws from biobanks and pharmacogenomic databases; Experience, which aggregates practitioner case history; Opinion, allowing for clinician-specific overrides; and Observation, which tracks patient-reported outcomes. This structure enables providers to perform natural-language queries, analyze pharmacogenomic interactions, and generate specialized reports spanning regenerative health and metabolic analysis.

CEO Len May emphasizes that the platform addresses a common bottleneck in modern healthcare: the gap between possessing biological data and applying it effectively. Dr. Allen Lawrence notes that the system offers a scalable model for personalized care by organizing complex inputs into actionable intelligence. EndoDNA, which operates with a 99.6% genotyping accuracy rate using Illumina sequencing, currently serves over 10,000 patients across nine countries. The BIOS dashboard is available immediately for licensed healthcare practitioners, maintaining HIPAA compliance while facilitating both research and clinical application.